• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, November 20, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Osaka Prognostic Score Predicts Two-Year Mortality in Reduced Ejection Fraction Heart Failure

by
November 14, 2026
in Health
Reading Time: 5 mins read
0
Osaka Prognostic Score Predicts Two-Year Mortality in Reduced Ejection Fraction Heart Failure

Osaka Prognostic Score Predicts Two-Year Mortality in Reduced Ejection Fraction Heart Failure

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A bedside prognostic tool combining routine measures of inflammation and nutritional status independently predicts two-year all-cause mortality in patients diagnosed with heart failure with reduced ejection fraction, according to a clinical investigation conducted at Zonguldak Bülent Ecevit University Faculty of Medicine Hospital in Türkiye. Researchers evaluated the Osaka Prognostic Score, an index derived from circulating levels of C-reactive protein, serum albumin, and total lymphocyte count, in a cohort of 198 patients treated for systolic heart failure between January 2023 and March 2024. The findings, published in Frontiers in Nutrition, show that patients presenting with higher baseline scores experienced significantly reduced survival over 24 months of follow-up, demonstrating that an easily calculated three-variable index can supply long-term risk stratification in this clinical population.

Heart failure with reduced ejection fraction, defined in the protocol as a left ventricular ejection fraction of 40 percent or less, represents approximately half of all heart failure hospitalizations and carries substantial long-term mortality. As documented in epidemiological cohorts cited by the research team, adult heart failure prevalence ranges from 1 to 2 percent, with historical community data showing mortality rates reaching 20 percent at one year and 53 percent at five years. While newer pharmacological agents and device therapies continue to shape management paradigms, accurately predicting long-term mortality risk remains essential for clinical decision-making. Malnutrition and elevated systemic inflammation frequently coexist in chronic heart failure, where gut congestion, impaired intestinal absorption, and persistent neurohormonal activation drive cardiac cachexia and progressive functional decline.

To capture these converging biological mechanisms, the clinical investigators focused on the Osaka Prognostic Score. Originally investigated in oncology settings, the scoring model has recently demonstrated prognostic relevance across acute coronary syndromes and transcatheter aortic valve implantation. The score assigns one integer point for each of three predetermined laboratory thresholds: a serum C-reactive protein concentration exceeding 10 milligrams per liter, a serum albumin level below 3.5 grams per deciliter or 35 grams per liter, and an absolute total lymphocyte count below 1,600 cells per microliter. Patients meeting none of these abnormality thresholds receive zero points, yielding an aggregate integer score ranging from 0 to 3 that integrates inflammatory activity, visceral protein synthesis, and cell-mediated immunological status from blood samples drawn during initial evaluation.

The study cohort comprised 198 adults evaluated at the tertiary hospital’s cardiology department as either hospitalized inpatients or outpatients, following the exclusion of individuals younger than 18 years, those lost to vital-status ascertainment, or those presenting with active systemic infection, sepsis, advanced hepatic dysfunction, autoimmune disease, or known malignancy. The final cohort had a median age of 52 years with an interquartile range of 43.0 to 58.0 years, and 83.8 percent were male. Across the two-year observation period, vital status was tracked through national mortality registries, during which 42 patients died, representing an overall mortality rate of 21.2 percent, while 156 patients survived. Left ventricular ejection fraction was measured via the Simpson method, with both survivors and non-survivors exhibiting a median ejection fraction of 20.0 percent.

Significant baseline discrepancies emerged between surviving and non-surviving patients across clinical, biochemical, and echocardiographic measures. Non-survivors presented with a significantly higher prevalence of diabetes mellitus at 73.8 percent compared with 37.8 percent among survivors, as well as an increased rate of right-sided heart failure at 76.2 percent versus 53.2 percent. Non-survivors also exhibited a higher mean New York Heart Association functional class of 2.8 compared to 2.1 in survivors. Echocardiographic evaluation demonstrated lower tricuspid annular plane systolic excursion among non-survivors, recording a median of 13.0 millimeters compared with 16.0 millimeters in survivors, reflecting poorer right ventricular systolic performance despite similar left ventricular diameters and ejection fractions.

Laboratory evaluations performed at the index visit revealed pronounced inflammatory and metabolic derangements among the patients who subsequently died. Median baseline C-reactive protein levels reached 12.7 milligrams per liter in non-survivors compared to 4.5 milligrams per liter in survivors, while serum albumin was lower at a median of 42 grams per liter compared to 44 grams per liter. Absolute lymphocyte counts were similarly depressed in non-survivors, registering a median of 1.4 times 10 to the ninth power cells per liter versus 1.9 times 10 to the ninth power cells per liter. When compiled into the composite index, non-survivors exhibited a median Osaka Prognostic Score of 2.0 with an interquartile range of 1.0 to 2.0, whereas survivors had a median baseline score of 0.0 with an interquartile range of 0.0 to 1.0.

Kaplan-Meier survival curves revealed a stepwise drop in cumulative survival across ascending score tiers over the 24 months of observation. Patients categorized with a score of 0 achieved an estimated mean survival duration of 23.4 months, experiencing only 3 deaths among 87 individuals, which corresponded to a 3.4 percent category mortality rate. In contrast, patients with a score of 1 exhibited a mean survival of 20.8 months with a 21.1 percent mortality rate, those with a score of 2 recorded a mean survival of 15.6 months with a 65.4 percent mortality rate, and patients presenting with the maximum score of 3 recorded a mean survival time of 11.8 months, with 6 deaths occurring among 9 individuals, yielding a category mortality rate of 66.7 percent.

In multivariable Cox proportional hazards modeling adjusted for preselected clinical covariates including age, sex, diabetes mellitus, and N-terminal pro-B-type natriuretic peptide, the Osaka Prognostic Score remained an independent predictor of two-year all-cause mortality. Each single-point increase in the score was associated with an adjusted hazard ratio of 2.637, with a 95 percent confidence interval spanning 1.864 to 3.731. Diabetes mellitus was the only other covariate that retained independent statistical significance in the multivariable model, yielding an adjusted hazard ratio of 2.676 with a 95 percent confidence interval of 1.284 to 5.576. Age, male sex, and natriuretic peptide levels were not statistically significant predictors of mortality in the fully adjusted model.

To evaluate potential pharmacological confounding arising from differences in guideline-directed medical therapies, the investigators performed a sensitivity analysis incorporating sodium-glucose cotransporter-2 inhibitor prescription, which was lower among non-survivors at 45.2 percent versus 62.2 percent in survivors. When SGLT2 inhibitor therapy was entered into the regression model, the Osaka Prognostic Score maintained its independent predictive association with two-year mortality, displaying a hazard ratio of 5.076 and a 95 percent confidence interval from 3.338 to 7.719. Proportional-hazards assumptions were formally assessed through interaction terms between covariates and log-transformed survival time, confirming the absence of time-dependent variation for the score.

Receiver operating characteristic curve comparisons evaluated through the DeLong test demonstrated that the Osaka Prognostic Score attained the highest overall area under the curve for two-year mortality discrimination at 0.824, with a 95 percent confidence interval of 0.759 to 0.890. Among the individual laboratory markers, the area under the curve reached 0.814 for C-reactive protein, 0.756 for serum albumin, and 0.719 for total lymphocyte count. Pairwise DeLong testing confirmed that the composite score significantly outperformed the total lymphocyte count alone. However, the score’s numerical edge over C-reactive protein and serum albumin did not reach statistical significance, reflecting comparable discriminatory capacity while providing a multidimensional assessment that captures overlapping nutritional and immune pathways.

The study authors acknowledged important methodological limitations inherent to their investigation, emphasizing that the single-center, retrospective framework and sample size of 198 patients restrict broader demographic generalizability. The cohort was characterized by a relatively young median age of 52 years, a predominantly male demographic, and a high background prevalence of cardiac implantable electronic devices exceeding 90 percent. Furthermore, the limited number of fatal events constrained the number of variables included in multivariable adjustments, and the small subpopulation of nine patients presenting with an initial score of 3 limited statistical precision in that highest risk tier.

The clinical cohort also integrated both ambulatory outpatients and hospitalized admissions without formal stratification between stable chronic disease and acute decompensation, introducing potential clinical heterogeneity into baseline measurements. Because laboratory parameters and the Osaka Prognostic Score were captured strictly at a single baseline index visit, the study could not assess longitudinal trajectory changes or differentiate cardiovascular death from non-cardiovascular causes. Emphasizing that observational designs cannot establish direct causality, the authors concluded that larger prospective multicenter studies will be necessary to validate these prognostic thresholds and determine whether incorporating the Osaka Prognostic Score into routine practice can improve management in patients with heart failure with reduced ejection fraction.

Subject of Research: Prognostic utility of the Osaka Prognostic Score in heart failure with reduced ejection fraction

Article Title: Prognostic value of the Osaka Prognostic Score for two-year mortality in patients with heart failure with reduced ejection fraction

Article References: Aladag, P., Erbay, I., Furkan Suner, A., & Avci, A. (2026). Prognostic value of the Osaka Prognostic Score for two-year mortality in patients with heart failure with reduced ejection fraction. Frontiers in Nutrition, 13, Article 1948699. https://doi.org/10.3389/fnut.2026.1948699

Image Credits: AI Generated

DOI: 10.3389/fnut.2026.1948699

Keywords: Osaka Prognostic Score, heart failure with reduced ejection fraction, HFrEF, cardiovascular mortality, C-reactive protein, serum albumin, total lymphocyte count, biomarkers, systemic inflammation, malnutrition, prognostic scoring, Kaplan-Meier survival, Cox regression analysis, DeLong test, retrospective cohort, cardiology

News Source: Ophelia Keating. (November 14, 2026). Osaka Prognostic Score Predicts Two-Year Mortality in Reduced Ejection Fraction Heart Failure. Scienmag.

Tags: biomarkersC-reactive proteinCardiologycardiovascular mortalityCox regression analysisDeLong testHeart Failure with Reduced Ejection FractionHFrEFKaplan-Meier survivalMalnutritionOsaka Prognostic Scoreprognostic scoringRetrospective CohortSerum albuminSystemic inflammationtotal lymphocyte count
Share12Tweet7Share2ShareShareShare1

Related Posts

Synthetic Green Tea Analog Enhances Macrophage Clearance of Intracellular Staphylococcal Infection

Synthetic Green Tea Analog Enhances Macrophage Clearance of Intracellular Staphylococcal Infection

November 20, 2026
Progressive Tension Sutures Associated With Lower Seroma Odds in Abdominoplasty Meta-Analysis

Progressive Tension Sutures Associated With Lower Seroma Odds in Abdominoplasty Meta-Analysis

November 20, 2026

Diclofenac Sodium Safely Prolongs Retrieval Timing and Improves Embryo Quality in IVF

November 20, 2026

Review Outlines Anesthetic Strategies and Perioperative Risks in Systemic Lupus Erythematosus

November 20, 2026

POPULAR NEWS

  • Narrative Review Explores Shared Biological Pathways Linking Obesity and Migraine Progression

    Narrative Review Explores Shared Biological Pathways Linking Obesity and Migraine Progression

    29 shares
    Share 12 Tweet 7
  • Semaglutide Preserves Muscle Function and Boosts Running Capacity in Obese Mice

    29 shares
    Share 12 Tweet 7
  • Millet Field Trials in Côte d’Ivoire Reveal Elite High-Yielding Local Landraces

    29 shares
    Share 12 Tweet 7
  • Survey Links Software AI Use to Governance Deficits and Training Gaps

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Copper Metal-Organic Framework Enables Sensitive Fluorescence Enhancement Sensor for Glyphosate Detection

Digital PCR Tracks Biocontrol Strains Suppressing Ochratoxin A in Aspergillus carbonarius

Synthetic Green Tea Analog Enhances Macrophage Clearance of Intracellular Staphylococcal Infection

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.